David Donabedian, CEO of Axial Biotherapeutics, chats with Mike Ward, head of content for Informa Pharma Insights, about using the microbiome to treat autism and why this R&D area is not just a passing phase. The pair discusses Axial’s technology, as well as the next steps for the emerging biotech which will enter the clinic in 2018. Axial is focused on the link between the human gut microbiome and the central nervous system; with its first clinical-stage asset the company is targeting patients with autism.
BIO-Europe® 2017: Axial CEO on microbiome use against autism
Get articles like this by email
Keep up to date with thought-leadership, interviews, surveys and more from our global network of industry experts